Natixis Advisors LLC Increases Position in Novo Nordisk A/S (NYSE:NVO)

Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,074,876 shares of the company’s stock after acquiring an additional 80,070 shares during the period. Novo Nordisk A/S accounts for approximately 0.7% of Natixis Advisors LLC’s investment portfolio, making the stock its 19th biggest position. Natixis Advisors LLC’s holdings in Novo Nordisk A/S were worth $366,125,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Gilliland Jeter Wealth Management LLC grew its stake in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $25,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $26,000. Finally, Halpern Financial Inc. lifted its holdings in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NVO. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $101.74 on Friday. The firm has a market cap of $456.56 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $118.58 and its two-hundred day moving average is $129.58.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.